中国医学前沿杂志（电子版）2025，Vol.17Issue(4)：12-18,7.DOI:10.12037/YXQY.2025.04-03
抗体药物偶联物在人表皮生长因子受体2表达乳腺癌治疗中的进展
Advances of antibody drug conjugates in the treatment of breast cancer with HER2 expression
李巧佴 1黎立喜 1李凤娟 1王佳玉 1马飞1
作者信息
- 1. 国家癌症中心 国家临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京 100021
- 折叠
摘要
Abstract
Antibody drug conjugates(ADCs)are a new type of anti-tumor drug,which have both the specificity of targeted drugs and the high anti-tumor activity of chemotherapy drugs and are highly promising for clinical application.In recent years,the treatment of breast cancer is entering the era of ADCs.ADCs represented by trastuzumab emtansine and trastuzumab deruxtecan have brought new breakthroughs in the treatment of patients with human epidermal growth factor receptor 2-positive(HER2+)breast cancer.In addition,the emergence of ADCs has introduced the concept of"HER2 low expression(HER2-low)"and brought survival benefits to breast cancer patients of this subtype.This review focuses on progress of ADCs in the treatment of breast cancer with HER2 expression.关键词
乳腺癌/人表皮生长因子受体2阳性/人表皮生长因子受体2低表达/抗体药物偶联物Key words
Breast cancer/Human epidermal growth factor receptor 2-positive/Human epidermal growth factor receptor 2 low expression/Antibody drug conjugates引用本文复制引用
李巧佴,黎立喜,李凤娟,王佳玉,马飞..抗体药物偶联物在人表皮生长因子受体2表达乳腺癌治疗中的进展[J].中国医学前沿杂志（电子版）,2025,17(4):12-18,7.
